Literature DB >> 8735577

Mortality of people with mental retardation in California with and without Down syndrome, 1986-1991.

D Strauss1, R K Eyman.   

Abstract

Mortality of people with mental retardation receiving services in California was examined. The large population (N = 118,653) enabled us to work directly with mortality rates at specific ages. Up to about age 35, mortality rates of people with Down syndrome were comparable to those of people with mental retardation due to other causes. Subsequently, the increase was much more rapid in the group with Down syndrome. Mortality rates of individuals with Down syndrome doubled every 6.4 years compared to 9.6 years for people without Down syndrome. Life tables were constructed; the remaining life expectancy of a 1-year-old child with Down syndrome with mild/moderate retardation was 55 years and with profound mental retardation, 43 years.

Entities:  

Mesh:

Year:  1996        PMID: 8735577

Source DB:  PubMed          Journal:  Am J Ment Retard        ISSN: 0895-8017


  15 in total

1.  Health conditions associated with aging and end of life of adults with Down syndrome.

Authors:  Anna J Esbensen
Journal:  Int Rev Res Ment Retard       Date:  2010

2.  Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease.

Authors:  Sarah B Martin; Amy L S Dowling; Joann Lianekhammy; Ira T Lott; Eric Doran; M Paul Murphy; Tina L Beckett; Frederick A Schmitt; Elizabeth Head
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

3.  Insulin receptor signaling mediates APP processing and β-amyloid accumulation without altering survival in a transgenic mouse model of Alzheimer's disease.

Authors:  Oliver Stöhr; Katharina Schilbach; Lorna Moll; Moritz M Hettich; Susanna Freude; F Thomas Wunderlich; Marianne Ernst; Johanna Zemva; Jens C Brüning; Wilhelm Krone; Michael Udelhoven; Markus Schubert
Journal:  Age (Dordr)       Date:  2011-11-06

Review 4.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

5.  Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B.

Authors:  Benjamin L Handen; Ann D Cohen; Umapathy Channamalappa; Peter Bulova; Sheila A Cannon; William I Cohen; Chester A Mathis; Julie C Price; William E Klunk
Journal:  Alzheimers Dement       Date:  2012-11       Impact factor: 21.566

6.  Alzheimer's Disease in Down Syndrome.

Authors:  Elizabeth Head; David Powell; Brian T Gold; Frederick A Schmitt
Journal:  Eur J Neurodegener Dis       Date:  2012-12

7.  Intellectual Disability, Mild Cognitive Impairment, and Risk for Dementia.

Authors:  Wayne P Silverman; Warren B Zigman; Sharon J Krinsky-McHale; Robert Ryan; Nicole Schupf
Journal:  J Policy Pract Intellect Disabil       Date:  2013-09-01

8.  Cost-effectiveness analysis of universal newborn screening for medium chain acyl-CoA dehydrogenase deficiency in France.

Authors:  Françoise F Hamers; Catherine Rumeau-Pichon
Journal:  BMC Pediatr       Date:  2012-06-08       Impact factor: 2.125

9.  Clinical benefits, costs, and cost-effectiveness of neonatal intensive care in Mexico.

Authors:  Jochen Profit; Diana Lee; John A Zupancic; LuAnn Papile; Cristina Gutierrez; Sue J Goldie; Eduardo Gonzalez-Pier; Joshua A Salomon
Journal:  PLoS Med       Date:  2010-12-14       Impact factor: 11.069

10.  Aging and down syndrome.

Authors:  Elizabeth Head; Wayne Silverman; David Patterson; Ira T Lott
Journal:  Curr Gerontol Geriatr Res       Date:  2012-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.